tiprankstipranks
Savara (SVRA)
NASDAQ:SVRA
US Market
SVRA
Savara
RESEARCH TOOLSreports

Savara (SVRA) Stock News & Sentiment

1,239 Followers
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
Premium
Ratings
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
5d ago
SVRA
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
Premium
Ratings
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
27d ago
SVRA
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
Premium
Ratings
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
28d ago
SVRA
Savara Signs Long-Term Lease for New Headquarters
Premium
Company Announcements
Savara Signs Long-Term Lease for New Headquarters
1M ago
8K
SVRA
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
Premium
Company Announcements
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
2M ago
SVRA
Savara Enters New Material Definitive Agreement and Obligation
Premium
Company Announcements
Savara Enters New Material Definitive Agreement and Obligation
3M ago
8K
SVRA
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
Premium
Ratings
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
3M ago
SVRA
More SVRA News >

SVRA News on the Web

Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
TipRanks News
Bullish
Savara announces MHRA accepted submission of Molbreevi MAA
TipRanks News
Bullish
Guggenheim Keeps Their Buy Rating on Savara (SVRA)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Edwards Lifesciences (EW)
TipRanks News
Bullish
Savara announces EMA validation of MAA for MOLBREEVI
TipRanks News
Bullish
Savara (SVRA) Gets a Buy from LifeSci Capital
TipRanks News
Bullish
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
TipRanks News
Bearish
Analysts Are Bullish on Top Healthcare Stocks: Savara (SVRA), Erasca (ERAS)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
SVRA
Sector Average
Media Buzz
This Week2 articles
Weekly Average2 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SVRA’s Media Buzz Sentiment?
2 articles about SVRA were published this week. In an average week, 2 articles are published.
    What is SVRA’s weekly average amount of articles?
    In an average week, 2 articles about SVRA are published.
      What is SVRA’s News Sentiment?
      100% of articles about SVRA were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week